Goodyear Tire & Rubber Co vs Regeneron Pharmaceuticals Inc — how do they compare? Goodyear Tire & Rubber Co trades at $6.1 (market cap $1.74B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 47.8× Goodyear Tire & Rubber Co's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.
| GT | REGN | |
|---|---|---|
Market Cap | $1.74B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $812.27 |
52-Week Low | $5.58 | $555.51 |
Enterprise Value | $9.09B | $77.90B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) is trading at $6.44, down 4.73% today, reflecting ongoing pressure from declining tire volumes and a challenging cost environment. The stock exhibits a bearish technical trend with oversold RSI levels, while fundamentals show a net loss of $1.72 billion in 2025 despite positive cash flow. Recent Q2 2026 results missed earnings expectations but beat revenue estimates, highlighting mixed operational performance amid market headwinds.
The outlook remains cautious with persistent profitability challenges and high debt levels offsetting low valuation multiples. Investment opportunity hinges on volume recovery and cost management improvements, but risks include sustained margin pressure and competitive threats. Analyst sentiment is mixed with a slight hold bias, underscoring the need for operational turnaround to drive shareholder value.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →